

REFERENCES

- Abdel Aleem S., Karim A.M. and Zarouk W.A. (1997):***
"Reduced effects of L-carnitine on glucose and fatty acid metabolism in myocytes isolated from diabetic rats".
Horm. Reab. Res.; 29(9): 430-435.
- Acetyl-L-carnitine Monograph (2010):*** Alternative Medical Review. 15(1):76-83
- Akerblom HK, Vaarala O, Hyöty H, Ilonen J, Knip M. (2002):***
Environmental factors in the etiology of type 1 diabetes.
American Journal of Medical Genetics. 115(1):18-29.
- Alemzadeh R. and Wyatt D. (2004):*** Diabetes mellitus in children. Behrman RE, Kliegman RM and Jenson HB (editor): Nelson Text Book of Pediatrics. Saunders 17th edition, P 1947-1972.
- Alemzadeh R. and Wyatt D. (2007):*** Diabetes mellitus in children; Behrman RE, Kliegman RM and Jenson HB (editor) Nelson textbook of pediatrics, Saunders 18th edition copyright; 2007.p.2404-2432.
- American Diabetes Association (ADA) (2003):*** Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care; 26:S5-S20.



- American Diabetes Association (ADA) (2006):*** Diagnosis and classification of Diabetes Mellitus. Diabetes Care; 29:S43-S48.
- American Diabetes Association (ADA) (2011):*** Diagnosis and classification of Diabetes Mellitus. Diabetes Care; 34:S62-S69.
- American Diabetes Association (ADA) (2011):*** Executive Summary: Standards of Medical Care in Diabetes. Diabetes Care; 34: S4-S10
- Arenas J., Rubio J.C., Martin M.A. and Campos Y. (1998):*** "Biological roles of L-carnitine in perinatal metabolism". Early Hum. Dev; 53 (Supl.): S43–50.
- Athanassakis I., Mouratidou M., Sakka P., Evangeliou A., Spilioti M., Vassiliadis S (2001):*** L-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment. International Immunopharmacology. 1:1813-22.
- Bakris GL. (2003):*** The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols. Postgrad Med. 2003 May;113(5):35-40, 43-4, 50.
- Bangstad H, Danne T, Deeb L, Jarosz-Chobot P, Urakami T, Hanas R (2007):*** Insulin treatment. Pediatric Diabetes 8(2), pages 88–102.



- Bangstad H., Danne T., Deeb L., Jarosz-Chobot P., Urakami T., Hanas R. (2009):** Insulin treatment in children and adolescents with diabetes. *Pediatric Diabetes* 10(s12), pages 82–99.
- Beker D J and Weber BB (1995):** Pathophysiology of DM. In: *Clinical Pediatric Endocrinology*. Edited by Charles GD Brook; p. 616-653.
- Bellinghiere G., Santoro D. and Calvani M. (2003):** "Carnitine and hemodialysis". *American Journal of Kidney Diseases*, March; 41(3).
- Bonnefont J.P, Djouadi F., Prip-Buus C., Gobin S., Munnich A. and Bastin J. (2004):** "Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects". *Mol Aspects Med.*; 25: 495–520.
- Brass E.P. (1995):** "Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients". *Clin. Ther.*; 17:176-185.
- Brass E.P. (2002):** Pivalate-Generating Prodrugs and Carnitine Homeostasis in Man. *Pharmacological Reviews*, 54:589-598.
- Brevetti G., Chiariello M. and Ferulano G. (1988):** "Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over



study". Circulation; 77: 767-773. (Quoted from: Kelly, 1998).

Brewster A.M. (1996): "Vitamins". In: Kaplan LA. and Pesce AJ. (eds.) "Clinical Chemistry". (3rd.ed), Mosby, London, Madrid, Mexico, p.780-800.

Buchta R., Nyhan W.L. and Broock R. (1993): "Carnitine in adolescents". Journal of adolescent health; 14: 440-441.

Büyükgebiz A, Cemeroglu AP, Böber E, Mohn A, Chiarelli F. (2001): Factors influencing remission phase in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. ; 14(9):1585-96.

Carter AL, Abney TO, Lapp DF. (1995): Biosynthesis and metabolism of carnitine. J Child Neurol. 10 (s2):3-7.Review.

Catargi B (2004): Current status and future of implantable insulin pumps for the treatment of diabetes. Expert Review of Medical Devices, 1(2) Pages 181-185.

Cederblad G., Hermansson G., Ludvigsson J. (1982): Plasma and urine carnitine in children with diabetes mellitus Clinica Chimica Acta, 125,207-217.



Cha Y.S. (2008): "Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid". Asia Pac J Clin Nutr; 17(S1):306-308.

Chaturvedi N., Bandinelli S., Mangili R., Penno G., Rottiers R.E. and Fuller J.H. (2001): Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold. Kidney International 60(1): 219–227.

Christopher Ryan C., Gurtunca N., Becker D. (2005): Hypoglycemia: A Complication of Diabetes Therapy in Children Affiliations Department of Psychiatry, University of Pittsburgh, Western Pennsylvania Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA. Pediatric Clinics of North America, 52, P. 1705-1733.

Cifone M.G., Alesse E. and Di Marzio L. (1997): "Effect of L-carnitine treatment in vivo on apoptosis and ceramide generation in peripheral blood lymphocytes from AIDS patients". Proc. Assoc. Am. Physicians; 109: 146-153. (Quoted from: Kelly, 1998).

Costa M., Canale D. and Filicori M. (1994): "L-carnitine in idiopathic asthenozoospermia: a multicenter study". Italian Study Group on Carnitine and Male Infertility. Andrologia; 26:155-159. (Quoted from: Kelly, 1998).



- Cryer P.E. (2004):** Diverse Causes of Hypoglycemia-Associated Autonomic Failure in Diabetes. *N Engl J Med.* 350:2272-2279.
- Cwik V.A. (2000):** "Disorders of lipid metabolism in skeletal muscle". *Neurologic Clinics*, February; 18(1).
- De Palo E, Gatti R, Sicolo N, Padovan D, Vettor R, Federspil G. (1981):** Plasma and urine free L-carnitine in human diabetes mellitus. *Acta Diabetol Lat.* 18(1):91-5.
- De Simone C., Tzantzoglou S. and Famularo G. (1993):** "High dose L-carnitine improves immunologic and metabolic parameters in AIDS patients". *Immunopharmacol Immunotoxicol* ; 15: 1-12. (Quoted from: Kelly, 1998).
- De Vivo D.C., Bohan T.P., Coulter D.L., Dreifuss F.E., Greenwood R.S., Nordli D.R., Sheilds D., Stafstrom C.E. and Tein I. (1998):** "L-carnitine supplementation in childhood epilepsy: current perspectives". *Epilepsia*, Nov; 39(1):1216-25.
- Deng S, Vatamaniuk M, Lian MM, Doliba N, Wang J, Bell E, Wolf B, Raper S, Matschinsky FM, Markmann JF. (2003):** Insulin gene transfer enhances the function of human islet grafts. *Diabetologia.* 46(3):386-93.
- Diaz M, Lopez F, Hernandez F, Urbina JA. (2000):** L-Carnitine effects on chemical composition of plasma



lipoproteins of rabbits fed with normal and high cholesterol diets. *Lipids*, 35(6):627-32.

Dobrowolski S.F., McKinney J.T., Di San Filippo C.A., Sim K.G., Wilcken B. and Longo N. (2005): "Validation of dye-binding/high-resolution thermal denaturation for the identification of mutations in the SLC22A5 gene". *Hum Mutat.*; 25: 306–313.

Donaghue KC, Chiarelli F, Trotta D, Allgrove J, Dahl-Jorgensen K. (2009): Microvascular and macrovascular complications associated with diabetes in children and adolescents. *Pediatric Diabetes*. 10 Suppl 12:195-203.

Donatelli S. (1987): "Carnitine Metabolism". In: Gitzelmen R., Baerlocher K. and Steinmann B (Eds.): "Carnitine in Medicine"(3rd edition), Stullgart, New York; P.90-100.

Donnelly R., Emslie-Smith A.M., Gardner I.D., Morris A.D. (2000): Vascular complications of diabetes. *BMJ*. 320(7241): 1062–1066.

Drash, A.F. Kuzana, Tzypneie and Leiter, E.H. (1994): Type 1 diabetes mellitus among children and adolescents around world. *West J. med.*, 160, 499-502.

El-Beshlawy A., El-Accaoui R., Abd El-Sattar M., Gamal El-Deen M.H., Youssry I., Shaheen N., Hamdy M., El-Ghamrawy M. and Taher A. (2006): " Effect of L -



carnitine on the physical fitness of thalassemic patients".
Annals of hematology; volume 86 ;(1): 31-34.

Evans A. (2003): "Dialysis-related carnitine disorders and levocarnitine pharmacology". American Journal of Kidney Diseases, April; 41(4).

Evans A.M., Faull R., Fornasini G., Lemanowicz E.F., Longo A. and Pace S. (2000): "Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis". Clin. Pharmacol. Ther; 68:238-249.

Fong KY. (2002): Immunotherapy in autoimmune diseases. Ann Acad Med Singapore. Nov; 31(6):702-6. Review.

Gabir M M, Hanson R L, Dabelea D, Imperatore G, Roumain J, Bennett P H, and Knowler W C (2000): The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care; 23:1108-1112.

Gale EAM (2001): Two cheers for inhaled insulin. The Lancet, 357(9253), Pages 324 – 325.

Gempel K., Kiechl S., Hofmann S., Lochmuller H., Kiechl-Kohlendorfer U., Willeit J., Sperl W., Rettinger A., Bieger I., Pongratz D., Gerbitz K.D. and Bauer M.F. (2002): "Screening for carnitine palmitoyltransferase II



deficiency by tandem mass spectrometry". J. Inherit. Metab. Dis.; 25: 17–27.

Genazzani A.D., Petraglia F., Algeri I. and Gastaldi M. (1992): "Acetyl-L-carnitine as possible drug in the treatment of hypothalamic amenorrhea". Acta Obstet. Gynecol. Scand.; 70:487-492.

Genuth S. (1982): Classification and diagnosis of diabetes mellitus. Medical Clinics of North America.; 66(6):1191-207.

Giannacopoulou C, Evangeliou A, Matalliotakis I, Relakis K, Sbirakis N, Hatzidaki E, Koumandakis E. (1998): Effects of gestation age and of birth weight in the concentration of carnitine in the umbilical plasma. Clinical and Experimental Obstetrics & Gynecology. 25:42-45.

Guarnieri G., Situlin R. and Biolo G. (2001): "Carnitine metabolism in uremia". American Journal of Kidney Diseases, October; 38(4).

Gylling H., Tuominen A.J., Veikko A. Koivisto A.V. and Miettinen A.T. (2004): Cholesterol Metabolism in Type 1 Diabetes. Diabetes; 53:2217-2222.

Habel, MA (1993): classification of diabetes mellitus. Lancet, 1:57.



- Haller, J.M., Atkinson, A.M and Schatz D. (2005):** Type 1 Diabetes Mellitus: Etiology, Presentation, and Management. *Pediatric Clinics of North America*, 52, P 1553-1578.
- Hathout H., Hartwick N., Fagoaga R., Colacino R., Sharkey J., Racine M., Nelsen-Cannarella S., and Mace W. (2003):** Clinical, Autoimmune, and HLA Characteristics of Children Diagnosed With Type 1 Diabetes Before 5 Years of Age. *Pediatrics* 2003; 111: 860-863.
- Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. (2009):** The diagnosis and management of monogenic diabetes in children and adolescents. *Pediatric Diabetes*. 10(12), P. 33–42.
- Hedayati S.S. (2006):** "Dialysis related carnitine disorder". *Seminars in Dialysis*; Vol 19, No 4 (July–August) pp. 323–328.
- Hendler S.S. and Rorvik D.R. (2001):** "PDR for nutritional supplements". Montvale: Medical Economics Company, Inc.
- Herzmann C., Johnson M.A. and Youle M. (2005):** "Long-term effect of acetyl-l-carnitine for antiretroviral toxic neuropathy". *HIV Clin Trials*; 6(6):344–350



- Holick MF (2005):** Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79: (3) 362-371.
- Hoppel C. (2003):** "The role of carnitine in normal and altered fatty acid metabolism". American Journal of Kidney Diseases, April; 41(4).
- Hug G. (1996):** "Metabolic disease". In Behrman RE; Kliegman RM.; Nelson WE. and Arvin AM.(eds.)."Nelson Textbook of Pediatrics". (15th ed). WB. Saunders, Philadelphia, London, Toronto, p. 389-390.
- Hummel M, Füchtenbusch M, Schenker M, and Ziegler A G (2000):** No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care 23:969-974.
- Hutchison, G.M. and Cocklwrn, F. (1986):** Disease of the endocrine system. The pancrease in practical pediatric problems. On Hutchism, J.H. and Cockbuim, F. (eds.). 6thed. Floyd-luke (Medical Books): 472
- Hyppönen E, Läärä E, Reunanen A, Järvelin M, Virtanen SM (2001):** Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. The Lancet, 358(9292), Pages 1500 – 1503.



International society for pediatric and adolescent diabetes (ISPAD). Consensus Guidelines (2009): Presentation and phases of diabetes. Couper J., Donahue K. Pediatric Diabetes; 10:13-16.

International society for pediatric and adolescent diabetes (ISPAD). (2007): Presentation and phases of diabetes. Couper J.J., Donaghue K.C., Pediatric Diabetes 2007; 8:44-47.

International society for pediatric and adolescent diabetes (ISPAD) Consensus Guidelines (2009): Nutritional management in children and adolescents with diabetes. Smart C, Aslander-van Vliet E, Waldron S. Pediatric Diabetes 10(s12), pages 100–117.

International society for pediatric and adolescent diabetes (ISPAD). Consensus Guidelines (2009): Definition, Epidemiology, Classification of diabetes in children and adolescents. Craig M, Hattersley A, Donaghue K. Pediatric Diabetes (Suppl 12); 10:3-12.

ISPAD clinical guidelines (2007): ISPAD clinical practice consensus guidelines 2006-2007. Definition, epidemiology and classification. Pediatric diabetes 7:343-51.



Ize-Ludlow D. and Sperling M.A. (2005): The Classification of Diabetes Mellitus: A Conceptual Framework. *Pediatric Clinics of North America*, 52, P 1533-1552.

Jun H.S, Yoon J.W. (2003): A new look at viruses in type 1 diabetes. *Diabetes Metab Res Rev.* 2003 Jan-Feb; 19(1):8-31.

Kamikawa T., Suzuki Y. and Kobayashi A. (1984): "Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris". *Jpn. Heart J.*; 25:587-597. (Quoted from: Kelly, 1998).

Karounos D.G. (2003): Current strategies for prevention of type I and II diabetes mellitus. In: *Endotext com* chapter 41, Dec, 16:1-18.

Kelley R.I. (1994): "The role of carnitine supplementation in valporic acid therapy". *Pediatrics*; 93(6):891-93.

Kelly G.S. (1998): "L-carnitine: Therapeutic applications of a conditionally essential amino acid". *Altern Med Rev*; 3(5):345-360.

Kerner J. and Hoppel C. (2000): "Fatty acid import into mitochondria". *Biochim Biophys Acta*; 1486:1-17.

Khardori R. (2011): Type 1 Diabetes Mellitus Treatment & Management. [Http://www.emedicine.com](http://www.emedicine.com).



Kimpimäki T, Erkkola M, Korhonen S, Kupila A, Virtanen SM, Ilonen J, Simell O, Knip M. (2001): Short-term exclusive breastfeeding predisposes young children with increased genetic risk of Type I diabetes to progressive beta-cell autoimmunity. *Diabetologia*.44(1):63-9.

Kishore P (2008): Diabetes Mellitus. The Merck Manuals. Online medical library.

Kitabchi A.E., Umpierrez G.E., Murphy M.B., Barrett E.J., Kreisberg R.A., Malone J.I., and Wall B.M.(2001): Management of Hyperglycemic Crises in patients with Diabetes. *Diabetes Care* 24:131-153.

Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, and Wall BM (2001): Management of Hyperglycemic Crises in Patients With Diabetes .*Diabetes Care* 24:131-153.

Klein JP, Waxman SG (2005): The brain in diabetes: molecular changes in neurons and their implications for end-organ damage. *Lancet Neurol*. 2003 Sep; 2(9):548-54.

Klemm T, Paschke R. (2000): Possible genetic causes for late complications of diabetes mellitus. *Med Klin (Munich)*. 95(1):31-9.



- Knip M. (2003):** Cow's milk and the new trials for prevention of Type 1 diabetes. J. endocrinological investigation; 26(3):265-257.
- Korkina M.V., Korchak G.M. and Kareva M.A. (1992):** "Effects of carnitine and cobamamide on the dynamics of mental work capacity in patients with anorexia nervosa". Zh. Nevropatol Psikhiatr. Im. S. S. Korsakova; 92: 99-102. (Quoted from: Kelly, 1998).
- Korman S.H., Waterham H.R., Gutman A., Jakobs C. and Wanders R.J. (2005):** "Novel metabolic and molecular findings in hepatic carnitine palmitoyltransferase I deficiency". Mol. Genet. Metab; 86: 337–343.
- Kurz C., Arbeiter K. and Obermair A. (1993):** "L-carnitine-betamethasone combination therapy versus betamethasone therapy alone in prevention of respiratory distress syndrome". Z. Geburtshilfe Perinatol.; Sep-Oct; 197(5):215-219. (Quoted from: Korkmaz et al., 2005).
- Kuzuya T, Shawkatova I, Fazekasova M, Micrhalkova D, Martinka F (2002):** Association of type 1 DM with HLA alleles. Diabetes care; 20:219-220.
- Lakey JR, Mirbolooki M, Shapiro AM. (2006):** Current status of clinical islet cell transplantation. Methods Mol Biol.; 333:47-104.



Lamb, H.W. (2010): Pediatric Type 1 Diabetes Mellitus.
Published on Mar. 2010.[Http://www.emedicine.com](http://www.emedicine.com)

Lamb, H.W. (2011): Pediatric Diabetic Ketoacidosis. Published
on Mar. 2011.[Http://www.emedicine.com](http://www.emedicine.com)

**Laviano A., Inui A., Marks D.L., Meguid M.M., Pichard C.,
Fanelli F.R. and Seelaender M. (2008):** "Neural control
of the anorexia-cachexia syndrome" *Am J Physiol
Endocrinol Metab* 295: E1000-E1008.

**Lenzi A., Lombardo F., Sgro P., Salacone P., Caponecchia L.,
Dondero F. and Gandini L. (2003):** "Use of carnitine
therapy in selected cases of male factor infertility: a double
blind cross-over trial". *Fertil Steril*; 79: 292-300.

**Levitt Katz LE, Swami S, Abraham M, Murphy KM, Jawad AF,
McKnight-Menci H, Berkowitz R (2005):**
Neuropsychiatric disorders at the presentation of type 2
diabetes mellitus in children. *Pediatric Diabetes*. 6(2), P.
84–89.

Longo N., Di San Filippo C.A. and Pasquali M. (2006):
"Disorders of carnitine transport and the carnitine cycle".
Am. J. Med. Genet. C. Semin. Med. Genet. May 15; 142C
(2): 77–85.



Malone JJ, Schocken DD, Morrison AD, Gilbert-Barness E. (1999): Diabetic cardiomyopathy and carnitine deficiency. *J Diabetes Complications*, 13(2):86-90.

Mamoulakis D, Galanakis E, Dionyssopoulou E, Evangeliou A and Sbyrakis S. : Carnitine deficiency in children and adolescents with type I diabetes. *Journal of diabetes and its complication*. (Abstract), 2004: 18; 271-274.

Manson-Bahr, P.E.C. and Apted, F.I.C. (1982): Non-infective disease, tropical diabetes in Manson's tropical diseases, 18th ed. The English Language Book Society, London, P.7.

Mathieu C, Badenhop K (2005): Vitamin D and type 1 diabetes mellitus: state of the art. *Trends Endocrinol Metab*. 2005; 16: 261-266.

Maurizio O., Francesco M., Luisa Z., Caterina N., Enrico M., Antonietta C. and Claudio M. (2006): "Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study". *Journal of the Peripheral Nervous System*. 11(1):72-76.

Mayes P.A. (1996): "Oxidation of fatty acids". In: Murray RK., Granner DK., Mayes PA. and Rod-Well VW.(eds.) "Harper's Biochemistry" (24th ed). Appleton and Lange, Norwallz-California P.225-233.



- McCarty MF. (2000):** Toward a wholly nutritional therapy for type 2 diabetes. *Med Hypotheses*, 54(3):483-7.
- McCurdy H.T. (1995):** Carnitine Deficiency. (Letters to the Editors) *Pediatric*; 96(6): 1174-1175.
- Merani S, Shapiro AM. (2006):** Current status of pancreatic islet transplantation. *Clin Sci (Lond)*.110(6):611-25.
- Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, Gasbarrini G. (1999):** L-carnitine improves glucose disposal in type 2 diabetic patients. *J Am Coll Nutr*. 18(1):77-82.
- Mitamura Y., Harada C. and Harada T. (2005):** Role of Cytokines and Trophic Factors in the Pathogenesis of Diabetic Retinopathy *Current Diabetes Reviews*. 1(1):73-81.
- Montgomery R., Conway T.W. and Spector A.A. (1990):** "Lipid Metabolism". In: "Biochemistry A Case Oriented Approach" (5th ed.). Eds, Mosby Company. Battimore-Philadelphia; p.417-420.
- National Diabetes Data Group (1979):** classification and diagnosis of diabetes mellitus and other categories of glucose tolerance. *Diabetes*, 28: 1039-57.



Neyestani TR, Djalali M, Pezeshki M, Siassi F, Eshraghian MR, Rajab A, Keshavarz A (2004): Serum antibodies to the major proteins found in cow's milk of Iranian patients with Type 1 diabetes mellitus. *Diabetes Nutr. Metab.* 17(2):76-83.

Orngreen M.C., Ejstrup R. and Vissing J. (2003): "Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency". *Neurology*; 61: 559–561.

Özmen B., Boyvada S. (2003): The relationship between self-monitoring of blood glucose control and glycosylated haemoglobin in patients with type 2 diabetes with and without diabetic retinopathy. *Journal of Diabetes and its Complications* 17(3): Pages 128-134.

Pace S., Longo A., Toon S., Rolan P. and Evans A.M. (2000): "Pharmacokinetics of propionyl-L-carnitine in humans: Evidence for saturable tubular reabsorption". *Br. J. Clin. Pharmacol*; 50:441-448.

Palmer JP (2001): Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse *J Clin Invest.* 108(1):31–33.Original Text

Petrovsky N. and Schatz D.A. (2003): The immunology of human type 1 diabetes. In: Pickup JC, Williams G (eds).



Textbook of Diabetes, Third Edition. Blackwell Science Ltd., Massachusetts, Oxford, Victoria, Berlin, p. 18.1-14.

Pickup JC and Williams G (2003): Clinical feature and management of diabetic nephropathy. Textbook of Diabetes 3rd edition. Marshall SM. Chapter53.

Pillar G, Schusheim G, Weiss R, Malhotra A, McCowen KC, Shlitner A, Peled N, Shehadeh N (2003): Interactions between hypoglycemia and sleep architecture in children with type 1 diabetes mellitus. J. Pediatr.142(2):163-8.

Poorabbas A, Fallah F, Bagdadchi J, Mahdavi R, Aliasgarzadeh A, Asadi Y, Koushavar H, Vahed Jabbari M. (2007): Determination of free L-carnitine levels in type II diabetic women with and without complications. European Journal of Clinical Nutrition. 61(7):892-5.

Powell B.R., Buist N.R.M. and Kennaway N.G. (1998): "Disorders of fatty acid metabolism". In: Campbell AGM. and McIntosh N. (eds.). "Forfar and Arneil's Textbook of Pediatrics". (5th ed.). Churchill Livingstone, London Edinburgh; p.1122-1129.

Pozzo A. M. (2011): Pediatric Type 2 Diabetes Mellitus. [Http://www.emedicine.com](http://www.emedicine.com) .

Pregant P, Schernthaner G, Legenstein E, Lienhart L, Bruck S, Schnack C, Kaiser E. (1991): Decreased plasma



carnitine in Type I diabetes mellitus. *Klinische Wochenschrift*. 69(12):511-6.

Proulx F, Lacroix J, Qureshi IA, Nadeau D, Gauthier M, Lambert M.(1997): Acquired carnitine abnormalities in critically ill children. *European Journal of Pediatrics*, 156(11):864-869.

Rahbar A.R., Shakerhosseini R., Saadat N., Taleban F., Pordal A. and Gollestan B. (2005): Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus. *European Journal of Clinical Nutrition*. 59: 592-596.

Raine J.E., Donaldson M.D.C, Gregory J.W. and Savage M.O. (2001): Diabetes mellitus. In *Practical Endocrinology and Diabetes in Children*. Blackwell science LTD.UK. Chapter1:1-28.

Rebouche CJ. (1999): "Carnitine". In: Shils ME., Olson JA., Shike M., Ross AC. (eds.). "Nutrition in Health and Disease". (9th ed.). Baltimore: Williams and Wilkins; p.505-512.

Rebouche CJ. and Seim H. (1998): "Carnitine metabolism and its regulation in microorganisms and mammals". *Annu. Rev. Nutr*; 18:39-61.



- Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ (2009):** Assessment and monitoring of glycemic control in children and adolescents with diabetes. *Pediatric Diabetes*. 10(s12), pages 71–81.
- Riley, L.J. Cooper. M and Norins, R.G. (1989):** Alkali therapy of diabetic ketoacidosis: Biochemical, physiologic, and clinical perspectives. *Diabetes/Metabolism Reviews*, 5, p 627–636.
- Robertson K, Adolfsson P, Scheiner G, Hanas R, Riddell MC. (2009):** Exercise in children and adolescents with diabetes. *Pediatric Diabetes*. 10 Suppl 12:154-68.
- Rubio-Gozalbo M.E., Bakker J.A., Waterham H.R. and Wanders R.J. (2004):** "Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects". *Mol Aspects Med.*; 25: 521–32
- Sanjeevi CB, Das AK, Shtauvere-Brameus A (2002):** BCG vaccination and GAD65 and IA-2 autoantibodies in autoimmune diabetes in southern India. *Ann N Y Acad Sci*. 958:293-6.
- Scaglia F. (2010):** Carnitine deficiency. [Http://www.emedicine.com](http://www.emedicine.com) published on April 2010.



Scaglia F. Longo N. (1999): Primary and secondary alterations of neonatal Carnitine metabolism. Seminars in perinatology . 23(2):152-61.

Schocken D.D., Cuthbertson D.D., Malone J.I. (2003): Carnitine corrects cardiomyopathic features of streptozotocin-induced diabetes mellitus in a rat model. 9 (5) P. S65.

Seim H., Eichler K. and Kleber H. (2001): "L-carnitine and its precursor, gamma-butyrobetaine". In: Kramer K., Hoppe P., Packer L. (eds.). "Nutraceuticals in health and disease prevention". New York: Marcel Dekker, Inc.; 217-256.

Sima AAF, Calvani M, Mehra M, and Amato A. (2005): Acetyl-l-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An analysis of two randomized placebo-controlled trials. Diabetes Care 28:89-94.

Soltesz G., Melegh B., & Sandor A. (1983): The relationship between carnitine and ketone body levels in diabetic children. Acta Paediatrica Scandinavia, 72, 511-515.

Sperling, M. A. (1996): Diabetes Mellitus: Behrman, R.E.; Kliegman, R.M. and Arvin, A.M. (editors). Nelson (Text book of Pediatric), 15th ed. Saunders Company Philadelphia, London Toronto, 1646-1664.



- Stanley C.A. and Bennett M.J. (2007):** "Disorders of Mitochondrial Fatty Acid β -Oxidation". In: Kliegman RM., Behrman RE., Jenson HB., Stanton BF.(eds.). "Nelson Textbook of Pediatrics"(18th ed.). WB Saunders, Philadelphia; p.567-572.
- Sutherland D, Gruessner A, Moudry-Munns K. (1994):** International Pancreas Transplant Registry report. Transplant Proc. 1994 Apr;26(2):407-11.
- Takiyama N. and Matsumoto K. (1998):** Age-and sex-related differences of serum carnitine in a Japanese population. Journal of the American College of Nutrition; 17(1):71-4.
- Tamamogullari N., Silig Y., Içagasioglu S. and Atalay A. (1999):** Carnitine Deficiency in Diabetes Mellitus Complications. Journal of Diabetes and its Complications, 13,251-253.
- Trucco M. (2004):** Stem cells and diabetes.Pediatr Diabetes. ; 5(S2):2-4.
- Valerie A. (2000):** "Disorders of lipid metabolism in skeletal muscle". Neurologic Clinics, February; 18(1).
- Vaz F.M. and Wanders R.J.A. (2002):** "Carnitine biosynthesis in mammals". Biochem J; 361: 417-429.



- Veldee MS. (1994):** "Nutrition". In: Burtis CA. and Ashwood ER.(eds.). "Tietz Textbook of Clinical Chemistry".(2nd ed.). WB. Saunders, Philadelphia, London, Toronto; p.1243-1246.
- Vendrame F., Zappaterreno A., Dotta F. (2004):** Markers of β -cell function in type 1 diabetes mellitus. *Minerva Medica* 2004 April; 95(2):79-84.
- Wagman AS, and Nuss JM. (2001):** Current therapies and emerging targets for the treatment of diabetes. *Current Pharmaceutical Design*, 7(6):417-50.
- Wennberg A, Hylander A, Sjöberg A, Arfvidsson B, Sandström R, Wickström I, Lundholm K. (1992):** Prevalence of carnitine depletion in critically ill patients with undernutrition. *Metabolism*. 41(2):165-71.
- Whitfield J., Smith T., Sollohub H., Sweetman L. and Roe C.R. (2003):** "Clinical effects of L-carnitine supplementation on apnea and growth in very low birth weight infants". *Pediatrics* Vol. 111 No. 3 March; P. 477-482.
- Winter S.C., Simon M., Zorn E.M., Szabo-Aczel S., Vance W.H., O'Hara T., Higashi L. (1989):** Relative carnitine insufficiency in children with type I diabetes mellitus.



American journal of Diseases of Children, 143(11):1337-9.

Winter WE, Schatz D. (2003): Prevention strategies for type 1 diabetes mellitus: current status and future directions. BioDrugs.; 17(1):39-64.

Yeslipek M.A., Hazar V. and Yegin O. (1998): "L-carnitine treatment in Beta-thalassemia major". Acta Hematologica; 100:162-163.

Young M.G. (2009): Pediatrics, Diabetic Ketoacidosis Clinical Presentation. [Http://www.emedicine.com](http://www.emedicine.com)

Zamora S., Benador N., Lacourt G. and Girardin E. (1995): "Renal handling of carnitine in preterm and term neonate". J. Pediatr; 127: 975-978.

Zhou X., Liu F., and Zhai S. (2007): " Effect of L-carnitine and/or L-acetyl-carnitine in nutrition treatment for male infertility: a systematic review". Asia Pac J Clin Nutr; 16 (Suppl 1):383-390.